Selected Current Trials
The Reading Center at Casey Eye Institute assists our research partners with the interpretation of ophthalmic measurements. The following selected clinical trials are representative of the types of trials for which we provide our expertise.
Leber Congenital Amaurosis
This study is investigating an experimental gene therapy in patients with LCA caused by mutations (changes) in the RPE65 gene. Study is currently enrolling patients age 6 years and older. To find more information about this trial, please visit www.clinicaltrials.gov. The study name is Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. The study identifier is NCT00749957.
Retintis Pigmentosa (RP)
RP is a severe disease of the eye characterized by progressive vision loss that eventually leads to total blindness. Currently there is no therapy to substantially alter or reverse the progression of RP. Recently, researchers have identified valproic acid (VPA) as a possible treatment agent. VPA is a promising drug since it is already FDA approved as an anti-seizure medication.
The study has recently been approved by the FDA. To view details, look for the study name Trial of Oral Valproic Acid for Retinitis Pigmentosa (VPA) at www.clinicaltrials.gov . The study identifier is NCT01233609.